# EDGAR Filing Document

**Accession Number:** 0001006028
**File Stem:** 0001493152-25-024276
**Filing Date:** 2025-11
**Character Count:** 10993
**Document Hash:** d8bc9380aea2da5cc58d766bfe7e8ec6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-024276.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001493152-25-024276

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251117

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PURE BIOSCIENCE, INC.
- **CENTRAL INDEX KEY:** 0001006028
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330530289
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14468
- **FILM NUMBER:** 251499737

**BUSINESS ADDRESS:**
- **STREET 1:** 771 JAMACHA ROAD #512
- **CITY:** EL CAJON
- **STATE:** CA
- **ZIP:** 92019
- **BUSINESS PHONE:** 619-596-8600

**MAIL ADDRESS:**
- **STREET 1:** 771 JAMACHA ROAD #512
- **CITY:** EL CAJON
- **STATE:** CA
- **ZIP:** 92019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PURE BIOSCIENCE
- **DATE OF NAME CHANGE:** 20031029

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PURE BIOSCIENCES
- **DATE OF NAME CHANGE:** 20031029

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INNOVATIVE MEDICAL SERVICES
- **DATE OF NAME CHANGE:** 19960122

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 17, 2025**

**PURE BIOSCIENCE, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-14468** | **33-0530289** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **771 Jamacha Rd., #512**<br> **El Cajon, California** | **92019** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (619) 596-8600**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 19, 2025, PURE Bioscience, Inc. (the "Company") announced that Jeffrey Kitchell has been appointed as the Company's President, in addition to his ongoing responsibilities as the Company's Corporate Secretary, effective as of November 17, 2025 (the "Effective Date"). Robert Bartlett will continue as the Company's Chief Executive Officer, principal executive officer and a member of the Company's board of directors, but stepped down from the position of President effective as of the Effective Date.

Mr. Kitchell, 55, has served as the Company's Vice President of Operations since April 2023. He also serves as the Company's Corporate Secretary, a role he has had since 2019. Mr. Kitchell oversees day-to-day operations, supports the Company's functions, and implements new structures and processes. Mr. Kitchell has held various roles since joining the Company in 2001. In his various roles, he managed the Company's legal affairs and helped secure its intellectual property. Before joining the Company, Mr. Kitchell held various leadership roles in companies ranging from small to large. Mr. Kitchell earned a Bachelor's Degree in Business Administration from the University of Phoenix.

It is anticipated that Mr. Kitchell will enter into the Company's standard form of indemnification agreement for the Company's officers and participate in other compensation and benefit programs generally available to the Company's executive officers. The terms of Mr. Kitchell's employment with the Company otherwise remain unchanged.

Except as set forth above, there are no arrangements or understandings between Mr. Kitchell and any other persons pursuant to which he was named to this position with the Company. There are no family relationships between Mr. Kitchell and any of the Company's directors or executive officers and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company issued a press release announcing the appointment of Mr. Kitchell, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 [Press Release, dated November 19, 2025.](ex99-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PURE BIOSCIENCE, INC.** | **PURE BIOSCIENCE, INC.** |
| Dated: November 19, 2025 | By: | */s/ Robert F. Bartlett* |
|  |  | Robert F. Bartlett |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**PURE Bioscience, Inc. Announces Leadership Promotions** 

El CAJON, CA – PURE Bioscience, Inc. (<u>OTCQB: PURE</u>) ("PURE" or the "Company"), creator of the patented non-toxic silver dihydrogen citrate (<u>SDC</u>) antimicrobial, today announced that the Company has appointed Jeff Kitchell as President, in addition to his ongoing responsibilities as Corporate Secretary, and Dolana Blount as Vice President of Operations, in addition to her ongoing responsibilities as Vice President of Regulatory Affairs, in each case, effective as of November 17, 2025. Robert Bartlett will continue in his role as a Board Member and Chief Executive Officer, but will step down as President. The decision to separate the President and CEO roles allows Mr. Bartlett to devote his attention more exclusively to his responsibilities as CEO.

Mr. Kitchell brings more than 24 years of experience with PURE, having served in multiple leadership roles, including most recently as Vice President of Operations. His deep operational expertise and long-standing dedication to the Company position him well to guide PURE's next phase of execution and strategic development.

Ms. Blount, a 27-year veteran of the Company, has held numerous leadership positions and played a significant role in the Company's intellectual property and product development. Her expanded responsibilities reflect her strong operational capabilities and continued leadership across critical areas of the business.

"These leadership appointments reinforce PURE's commitment to fostering strong internal talent," said Mr. Bartlett. "Mr. Kitchell's proven track record has been instrumental in advancing our new vision and ongoing business transformation. Ms. Blount's insight, dedication, and unwavering commitment to our mission have been vital to guiding the Company through its evolution. Their leadership will continue to support PURE's focus on innovation, operational excellence, and long-term growth."

**About PURE Bioscience, Inc.**

PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing its proprietary antimicrobial products, primarily in the food and beverage industry. PURE provides solutions to combat the health and environmental challenges posed by pathogens and ensure hygienic control. PURE's technology platform is based on patented, stabilized ionic silver, and its products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC distinguishes itself from existing products in the marketplace by its superior efficacy, reduced toxicity, and its ability to mitigate bacterial resistance. Additional information on PURE is available at <u>www.purebio.com.</u>

**Forward-looking Statements**: *Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company's leadership and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including its Form 10-K for the fiscal year ended July 31, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.*

 

**Contact:**

Jeff Kitchell, President and Corporate Secretary

PURE Bioscience, Inc.

Phone: 619-596-8600